# 2026-19921: FDA: That sulfa pill wasn't yanked for being bunk

2026-19921, Determination That SULFADIAZINE (Sulfadiazine) Tablet, 500 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-09-29, effective 2026-09-29; PRIA reads it as touching household money (as of 2026-10-06).

- Canonical: https://policyrisk.com/federal-register/2026-19921
- As of: 2026-10-06
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-19921
- Title: Determination That SULFADIAZINE (Sulfadiazine) Tablet, 500 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 61407
- Published: 2026-09-29
- Effective: 2026-09-29
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-06

## In one line

FDA: That sulfa pill wasn't yanked for being bunk

## Summary

The FDA has decided that the 500 mg sulfadiazine tablet wasn’t taken off the market because it was unsafe or didn’t work. This means generic drug makers can now apply to sell their versions, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back.

## Abstract

The Food and Drug Administration (FDA or Agency) has determined that SULFADIAZINE (sulfadiazine) tablet, 500 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for SULFADIAZINE (sulfadiazine) tablet, 500 mg, if all other legal and regulatory requirements are met.

## Effects PRIA read

- Generic Makers Can Seek Approval Now: benefit, medium. The FDA determined that SULFADIAZINE (sulfadiazine) tablet, 500 mg, was not withdrawn from sale for reasons of safety or effectiveness. Because of that determination, abbreviated new drug applications (ANDAs) that refer to this listed drug may be approved if they meet all other legal and regulatory…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-19921 on federalregister.gov](https://www.federalregister.gov/documents/2026/09/29/2026-19921/determination-that-sulfadiazine-sulfadiazine-tablet-500-milligrams-was-not-withdrawn-from-sale-for)
- [2026-19921 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-09-29/pdf/2026-19921.pdf)

## Related
- [Previous: 2026-19920, Sunshine Act; Open Commission Meeting Wednesday, September 30, 2026](https://policyrisk.com/federal-register/2026-19920)
- [Next: 2026-19922, Information Collections Being Submitted for Review and Approval to Office of Ma…](https://policyrisk.com/federal-register/2026-19922)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-19921 (as of 2026-10-06).
